Continuous manufacturing lines for pharmaceuticals refer to an advanced method of drug production where the entire process, from raw material input to final product output, occurs in a seamless, nonstop sequence. This approach contrasts with traditional batch manufacturing, which involves producing drugs in discrete, separate steps with intervals for quality checks and transfers between stages.
Regulatory bodies like the FDA and EMA support the adoption of continuous manufacturing due to its potential to improve product quality and manufacturing efficiency. However, implementing continuous manufacturing requires rigorous validation and compliance with regulatory standards to ensure the safety and efficacy of the pharmaceutical products.
The global Continuous Manufacturing lines for Pharma market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淐ontinuous Manufacturing lines for Pharma Industry Forecast鈥� looks at past sales and reviews total world Continuous Manufacturing lines for Pharma sales in 2022, providing a comprehensive analysis by region and market sector of projected Continuous Manufacturing lines for Pharma sales for 2023 through 2029. With Continuous Manufacturing lines for Pharma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Continuous Manufacturing lines for Pharma industry.
This Insight Report provides a comprehensive analysis of the global Continuous Manufacturing lines for Pharma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Continuous Manufacturing lines for Pharma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Continuous Manufacturing lines for Pharma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Continuous Manufacturing lines for Pharma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Continuous Manufacturing lines for Pharma.
United States market for Continuous Manufacturing lines for Pharma is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Continuous Manufacturing lines for Pharma is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Continuous Manufacturing lines for Pharma is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Continuous Manufacturing lines for Pharma players cover GEA Group, Glatt Group, IMA Group, LB Bohle, Hovione, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Continuous Manufacturing lines for Pharma market by product type, application, key players and key regions and countries.
Segmentation by Type:
Solid Dosage Forms
Liquid Dosage Forms
Segmentation by Application:
Pharmaceutical Companies
Contract Manufacturing Organization
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Solid Dosage Forms
Liquid Dosage Forms
Segmentation by Application:
Pharmaceutical Companies
Contract Manufacturing Organization
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GEA Group
Glatt Group
IMA Group
LB Bohle
Hovione
Continuus Pharmaceuticals
Syntegon
Repligen
Dec Group
Recipharm
Shionogi
SK biotek
Korsch
Chemtrix
Fette Compacting
Gericke
Thermo Fisher Scientific
Coperion
Siemens
Copa-DATA
Asymchem Laboratories(Tianjin)
Porton Pharma Solutions
Zhejiang Canaan Tech
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Continuous Manufacturing lines for Pharma Market Size 2019-2030
2.1.2 Continuous Manufacturing lines for Pharma Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Continuous Manufacturing lines for Pharma by Country/Region, 2019, 2023 & 2030
2.2 Continuous Manufacturing lines for Pharma Segment by Type
2.2.1 Solid Dosage Forms
2.2.2 Liquid Dosage Forms
2.3 Continuous Manufacturing lines for Pharma Market Size by Type
2.3.1 Continuous Manufacturing lines for Pharma Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Continuous Manufacturing lines for Pharma Market Size Market Share by Type (2019-2024)
2.4 Continuous Manufacturing lines for Pharma Segment by Application
2.4.1 Pharmaceutical Companies
2.4.2 Contract Manufacturing Organization
2.5 Continuous Manufacturing lines for Pharma Market Size by Application
2.5.1 Continuous Manufacturing lines for Pharma Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Continuous Manufacturing lines for Pharma Market Size Market Share by Application (2019-2024)
3 Continuous Manufacturing lines for Pharma Market Size by Player
3.1 Continuous Manufacturing lines for Pharma Market Size Market Share by Player
3.1.1 Global Continuous Manufacturing lines for Pharma Revenue by Player (2019-2024)
3.1.2 Global Continuous Manufacturing lines for Pharma Revenue Market Share by Player (2019-2024)
3.2 Global Continuous Manufacturing lines for Pharma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Continuous Manufacturing lines for Pharma by Region
4.1 Continuous Manufacturing lines for Pharma Market Size by Region (2019-2024)
4.2 Global Continuous Manufacturing lines for Pharma Annual Revenue by Country/Region (2019-2024)
4.3 Americas Continuous Manufacturing lines for Pharma Market Size Growth (2019-2024)
4.4 APAC Continuous Manufacturing lines for Pharma Market Size Growth (2019-2024)
4.5 Europe Continuous Manufacturing lines for Pharma Market Size Growth (2019-2024)
4.6 Middle East & Africa Continuous Manufacturing lines for Pharma Market Size Growth (2019-2024)
5 Americas
5.1 Americas Continuous Manufacturing lines for Pharma Market Size by Country (2019-2024)
5.2 Americas Continuous Manufacturing lines for Pharma Market Size by Type (2019-2024)
5.3 Americas Continuous Manufacturing lines for Pharma Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Continuous Manufacturing lines for Pharma Market Size by Region (2019-2024)
6.2 APAC Continuous Manufacturing lines for Pharma Market Size by Type (2019-2024)
6.3 APAC Continuous Manufacturing lines for Pharma Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Continuous Manufacturing lines for Pharma Market Size by Country (2019-2024)
7.2 Europe Continuous Manufacturing lines for Pharma Market Size by Type (2019-2024)
7.3 Europe Continuous Manufacturing lines for Pharma Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Continuous Manufacturing lines for Pharma by Region (2019-2024)
8.2 Middle East & Africa Continuous Manufacturing lines for Pharma Market Size by Type (2019-2024)
8.3 Middle East & Africa Continuous Manufacturing lines for Pharma Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Continuous Manufacturing lines for Pharma Market Forecast
10.1 Global Continuous Manufacturing lines for Pharma Forecast by Region (2025-2030)
10.1.1 Global Continuous Manufacturing lines for Pharma Forecast by Region (2025-2030)
10.1.2 Americas Continuous Manufacturing lines for Pharma Forecast
10.1.3 APAC Continuous Manufacturing lines for Pharma Forecast
10.1.4 Europe Continuous Manufacturing lines for Pharma Forecast
10.1.5 Middle East & Africa Continuous Manufacturing lines for Pharma Forecast
10.2 Americas Continuous Manufacturing lines for Pharma Forecast by Country (2025-2030)
10.2.1 United States Market Continuous Manufacturing lines for Pharma Forecast
10.2.2 Canada Market Continuous Manufacturing lines for Pharma Forecast
10.2.3 Mexico Market Continuous Manufacturing lines for Pharma Forecast
10.2.4 Brazil Market Continuous Manufacturing lines for Pharma Forecast
10.3 APAC Continuous Manufacturing lines for Pharma Forecast by Region (2025-2030)
10.3.1 China Continuous Manufacturing lines for Pharma Market Forecast
10.3.2 Japan Market Continuous Manufacturing lines for Pharma Forecast
10.3.3 Korea Market Continuous Manufacturing lines for Pharma Forecast
10.3.4 Southeast Asia Market Continuous Manufacturing lines for Pharma Forecast
10.3.5 India Market Continuous Manufacturing lines for Pharma Forecast
10.3.6 Australia Market Continuous Manufacturing lines for Pharma Forecast
10.4 Europe Continuous Manufacturing lines for Pharma Forecast by Country (2025-2030)
10.4.1 Germany Market Continuous Manufacturing lines for Pharma Forecast
10.4.2 France Market Continuous Manufacturing lines for Pharma Forecast
10.4.3 UK Market Continuous Manufacturing lines for Pharma Forecast
10.4.4 Italy Market Continuous Manufacturing lines for Pharma Forecast
10.4.5 Russia Market Continuous Manufacturing lines for Pharma Forecast
10.5 Middle East & Africa Continuous Manufacturing lines for Pharma Forecast by Region (2025-2030)
10.5.1 Egypt Market Continuous Manufacturing lines for Pharma Forecast
10.5.2 South Africa Market Continuous Manufacturing lines for Pharma Forecast
10.5.3 Israel Market Continuous Manufacturing lines for Pharma Forecast
10.5.4 Turkey Market Continuous Manufacturing lines for Pharma Forecast
10.6 Global Continuous Manufacturing lines for Pharma Forecast by Type (2025-2030)
10.7 Global Continuous Manufacturing lines for Pharma Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Continuous Manufacturing lines for Pharma Forecast
11 Key Players Analysis
11.1 GEA Group
11.1.1 GEA Group Company Information
11.1.2 GEA Group Continuous Manufacturing lines for Pharma Product Offered
11.1.3 GEA Group Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 GEA Group Main Business Overview
11.1.5 GEA Group Latest Developments
11.2 Glatt Group
11.2.1 Glatt Group Company Information
11.2.2 Glatt Group Continuous Manufacturing lines for Pharma Product Offered
11.2.3 Glatt Group Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Glatt Group Main Business Overview
11.2.5 Glatt Group Latest Developments
11.3 IMA Group
11.3.1 IMA Group Company Information
11.3.2 IMA Group Continuous Manufacturing lines for Pharma Product Offered
11.3.3 IMA Group Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 IMA Group Main Business Overview
11.3.5 IMA Group Latest Developments
11.4 LB Bohle
11.4.1 LB Bohle Company Information
11.4.2 LB Bohle Continuous Manufacturing lines for Pharma Product Offered
11.4.3 LB Bohle Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 LB Bohle Main Business Overview
11.4.5 LB Bohle Latest Developments
11.5 Hovione
11.5.1 Hovione Company Information
11.5.2 Hovione Continuous Manufacturing lines for Pharma Product Offered
11.5.3 Hovione Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Hovione Main Business Overview
11.5.5 Hovione Latest Developments
11.6 Continuus Pharmaceuticals
11.6.1 Continuus Pharmaceuticals Company Information
11.6.2 Continuus Pharmaceuticals Continuous Manufacturing lines for Pharma Product Offered
11.6.3 Continuus Pharmaceuticals Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Continuus Pharmaceuticals Main Business Overview
11.6.5 Continuus Pharmaceuticals Latest Developments
11.7 Syntegon
11.7.1 Syntegon Company Information
11.7.2 Syntegon Continuous Manufacturing lines for Pharma Product Offered
11.7.3 Syntegon Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Syntegon Main Business Overview
11.7.5 Syntegon Latest Developments
11.8 Repligen
11.8.1 Repligen Company Information
11.8.2 Repligen Continuous Manufacturing lines for Pharma Product Offered
11.8.3 Repligen Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Repligen Main Business Overview
11.8.5 Repligen Latest Developments
11.9 Dec Group
11.9.1 Dec Group Company Information
11.9.2 Dec Group Continuous Manufacturing lines for Pharma Product Offered
11.9.3 Dec Group Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Dec Group Main Business Overview
11.9.5 Dec Group Latest Developments
11.10 Recipharm
11.10.1 Recipharm Company Information
11.10.2 Recipharm Continuous Manufacturing lines for Pharma Product Offered
11.10.3 Recipharm Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Recipharm Main Business Overview
11.10.5 Recipharm Latest Developments
11.11 Shionogi
11.11.1 Shionogi Company Information
11.11.2 Shionogi Continuous Manufacturing lines for Pharma Product Offered
11.11.3 Shionogi Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Shionogi Main Business Overview
11.11.5 Shionogi Latest Developments
11.12 SK biotek
11.12.1 SK biotek Company Information
11.12.2 SK biotek Continuous Manufacturing lines for Pharma Product Offered
11.12.3 SK biotek Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 SK biotek Main Business Overview
11.12.5 SK biotek Latest Developments
11.13 Korsch
11.13.1 Korsch Company Information
11.13.2 Korsch Continuous Manufacturing lines for Pharma Product Offered
11.13.3 Korsch Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Korsch Main Business Overview
11.13.5 Korsch Latest Developments
11.14 Chemtrix
11.14.1 Chemtrix Company Information
11.14.2 Chemtrix Continuous Manufacturing lines for Pharma Product Offered
11.14.3 Chemtrix Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Chemtrix Main Business Overview
11.14.5 Chemtrix Latest Developments
11.15 Fette Compacting
11.15.1 Fette Compacting Company Information
11.15.2 Fette Compacting Continuous Manufacturing lines for Pharma Product Offered
11.15.3 Fette Compacting Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Fette Compacting Main Business Overview
11.15.5 Fette Compacting Latest Developments
11.16 Gericke
11.16.1 Gericke Company Information
11.16.2 Gericke Continuous Manufacturing lines for Pharma Product Offered
11.16.3 Gericke Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Gericke Main Business Overview
11.16.5 Gericke Latest Developments
11.17 Thermo Fisher Scientific
11.17.1 Thermo Fisher Scientific Company Information
11.17.2 Thermo Fisher Scientific Continuous Manufacturing lines for Pharma Product Offered
11.17.3 Thermo Fisher Scientific Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Thermo Fisher Scientific Main Business Overview
11.17.5 Thermo Fisher Scientific Latest Developments
11.18 Coperion
11.18.1 Coperion Company Information
11.18.2 Coperion Continuous Manufacturing lines for Pharma Product Offered
11.18.3 Coperion Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Coperion Main Business Overview
11.18.5 Coperion Latest Developments
11.19 Siemens
11.19.1 Siemens Company Information
11.19.2 Siemens Continuous Manufacturing lines for Pharma Product Offered
11.19.3 Siemens Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Siemens Main Business Overview
11.19.5 Siemens Latest Developments
11.20 Copa-DATA
11.20.1 Copa-DATA Company Information
11.20.2 Copa-DATA Continuous Manufacturing lines for Pharma Product Offered
11.20.3 Copa-DATA Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Copa-DATA Main Business Overview
11.20.5 Copa-DATA Latest Developments
11.21 Asymchem Laboratories(Tianjin)
11.21.1 Asymchem Laboratories(Tianjin) Company Information
11.21.2 Asymchem Laboratories(Tianjin) Continuous Manufacturing lines for Pharma Product Offered
11.21.3 Asymchem Laboratories(Tianjin) Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 Asymchem Laboratories(Tianjin) Main Business Overview
11.21.5 Asymchem Laboratories(Tianjin) Latest Developments
11.22 Porton Pharma Solutions
11.22.1 Porton Pharma Solutions Company Information
11.22.2 Porton Pharma Solutions Continuous Manufacturing lines for Pharma Product Offered
11.22.3 Porton Pharma Solutions Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 Porton Pharma Solutions Main Business Overview
11.22.5 Porton Pharma Solutions Latest Developments
11.23 Zhejiang Canaan Tech
11.23.1 Zhejiang Canaan Tech Company Information
11.23.2 Zhejiang Canaan Tech Continuous Manufacturing lines for Pharma Product Offered
11.23.3 Zhejiang Canaan Tech Continuous Manufacturing lines for Pharma Revenue, Gross Margin and Market Share (2019-2024)
11.23.4 Zhejiang Canaan Tech Main Business Overview
11.23.5 Zhejiang Canaan Tech Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
